Buy Rating Affirmed: Jasper Therapeutics’ Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market

7h ago, source:

Analyst Tim Chiang from Capital One Financial maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report) and keeping the ...

Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

13d ago, source:

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including ...

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

17h ago, source: Yahoo Finance

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its ...

After Karuna's acquisition, former CEO lands new gig at Cambridge biotech

2d ago, source:

Bill Meury is now leading a clinical-stage Cambridge company developing treatments for cardiovascular diseases.

Amgen: The Giant With An Impressive Pipeline

10d ago, source: Seeking Alpha

Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...

Why Janux Therapeutics Stock Is Crushing It This Week

on MSN ago, source:

Janux's silence about a potential acquisition deal could be golden. Janux Therapeutics ( JANX 12.06%) stock is crushing it. The stock was up 42.4% for the week as of market close on Thursday, ...

Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition

6d ago, source: BioSpace

Cerevel Therapeutics on Thursday reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can ...

Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk

9d ago, source:

While many bigger pharma names might desire entry into huge GLP-1 weight loss market, Pfizer makes logical sense on several ...

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

1d ago, source:

Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision ...

Nocturne Acquisition Corporation Announces Termination and Liquidation of Trust Account

7d ago, source: Morningstar

2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that it will be unable to complete an initial business combination with Cognos Therapeutics, Inc. and intends to ...

Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

13d ago, source: Benzinga.com

Concurrently, Century announced pipeline and platform enhancements through the acquisition of Clade Therapeutics Inc., a privately held biotech company focused on discovering and delivering ...